BG104436A - The administration of macrolides for the treatment of cancer and macular degeneration - Google Patents

The administration of macrolides for the treatment of cancer and macular degeneration

Info

Publication number
BG104436A
BG104436A BG104436A BG10443600A BG104436A BG 104436 A BG104436 A BG 104436A BG 104436 A BG104436 A BG 104436A BG 10443600 A BG10443600 A BG 10443600A BG 104436 A BG104436 A BG 104436A
Authority
BG
Bulgaria
Prior art keywords
administration
treatment
macular degeneration
macrolides
cancer
Prior art date
Application number
BG104436A
Other languages
Bulgarian (bg)
Inventor
Yat Sun Or
Jacob Plattner
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG104436A publication Critical patent/BG104436A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to a method for the treatment of tumours and macular degeneration in humans and animals which includes the administration of a compound selected from the group consisting of compounds with the formula and to pharmaceutical composition including a pharmaceutically acceptable carrier and a compound of the above group. 6 claims
BG104436A 1997-10-31 2000-05-15 The administration of macrolides for the treatment of cancer and macular degeneration BG104436A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Publications (1)

Publication Number Publication Date
BG104436A true BG104436A (en) 2000-12-29

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104436A BG104436A (en) 1997-10-31 2000-05-15 The administration of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (en)
JP (1) JP2001521891A (en)
KR (1) KR20010031577A (en)
CN (1) CN1278178A (en)
AR (1) AR043071A1 (en)
AU (1) AU1206799A (en)
BG (1) BG104436A (en)
BR (1) BR9813318A (en)
CA (1) CA2307850A1 (en)
HU (1) HUP0100012A3 (en)
IL (1) IL135518A0 (en)
NO (1) NO20002189L (en)
PL (1) PL340604A1 (en)
SK (1) SK6172000A3 (en)
TR (1) TR200001147T2 (en)
WO (1) WO1999022722A2 (en)
ZA (1) ZA989885B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4858801A (en) 2000-04-13 2001-10-30 Biotica Tech Ltd Hybrid glycosylated products and their production and use
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN108101948A (en) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 Macrocyclic compound and its making and use method
EP1723159B1 (en) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
WO2006034478A2 (en) 2004-09-23 2006-03-30 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
KR101387456B1 (en) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 Liquid formulations for treatment of diseases or conditions
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP1934237A2 (en) 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
EP1928893A2 (en) 2005-08-24 2008-06-11 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
CN106317146B (en) * 2015-06-18 2019-06-21 沈阳药科大学 Bicyclic clarithomycin derivative and its as tumour cell increment inhibitor purposes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
TR200001147T2 (en) 2000-08-21
KR20010031577A (en) 2001-04-16
CA2307850A1 (en) 1999-05-14
ZA989885B (en) 1999-05-05
NO20002189L (en) 2000-06-28
EP1027060A2 (en) 2000-08-16
NO20002189D0 (en) 2000-04-27
CN1278178A (en) 2000-12-27
PL340604A1 (en) 2001-02-12
WO1999022722A2 (en) 1999-05-14
BR9813318A (en) 2000-08-22
IL135518A0 (en) 2001-05-20
AU1206799A (en) 1999-05-24
JP2001521891A (en) 2001-11-13
HUP0100012A2 (en) 2001-05-28
HUP0100012A3 (en) 2003-07-28
AR043071A1 (en) 2005-07-20
WO1999022722A3 (en) 1999-08-05
SK6172000A3 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
TR200200717T2 (en) Therapeutic quinazoline derivatives.
CA2275889A1 (en) Formulation and method for treating neoplasms by inhalation
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
EP1033981A4 (en) Formulations and methods for reducing toxicity of antineoplastic agents
HK1039328A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
HUP0204519A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
BG103417A (en) Condensed pyrimidine bicyclic derivatives
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
PL342614A1 (en) Anticarcinogenic drugs
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
HUT64013A (en) Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ZA937558B (en) New taxane derivatives, their preparation and pharmaceutical compositions which contain them
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
UA42733C2 (en) Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity
GB9907571D0 (en) Compounds
IL165086A (en) Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG106831A (en) Compound and method for the treatment of pain
BG103985A (en) Multicyclic derivatives of erythromycin